MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study

Ayman Tourbah 1, 2, * Olivier Gout 3 Alain Vighetto 4, 5 Véronique Deburghgraeve 6 Jean Pelletier 6, 7 Caroline Papeix 8 Christine Lebrun-Frenay 9 Pierre Labauge 10 David Brassat 11 Ahmed Toosy 12 David-Axel Laplaud 13, 14 Olivier Outteryck 15 Thibault Moreau 16 Marc Debouverie 17 Pierre Clavelou 18 Olivier Heinzlef 19 Jérôme de Sèze 20 Gilles Defer 21 Frédéric Sedel 22 Carl Arndt 1
Abstract : BACKGROUND: Chronic visual loss is a disabling feature in patients with multiple sclerosis (MS). It was recently shown that MD1003 (high-dose pharmaceutical-grade biotin or hdPB) may improve disability in patients with progressive MS. OBJECTIVE: The aim of this study was to evaluate whether MD1003 improves vision compared with placebo in MS patients with chronic visual loss. METHODS: The MS-ON was a 6-month, randomized, double-blind, placebo-controlled study with a 6-month open-label extension phase. Adult patients with MS-related chronic visual loss of at least one eye [visual acuity (VA) below 0.5 decimal chart] were randomized 2:1 to oral MD1003 300 mg/day or placebo. The selected eye had to show worsening of VA within the past 3 years following either acute optic neuritis (AON) or slowly progressive optic neuropathy (PON). The primary endpoint was the mean change from baseline to month 6 in VA measured in logarithm of the minimum angle of resolution (logMAR) at 100% contrast of the selected eye. Visually evoked potentials, visual field, retinal nerve fiber layer (RNFL) thickness, and health outcomes were also assessed. RESULTS: Ninety-three patients received MD1003 (n = 65) or placebo (n = 28). The study did not meet its primary endpoint, as the mean change in the primary endpoint was nonsignificantly larger (p = 0.66) with MD1003 (- 0.061 logMAR, + 3.1 letters) than with placebo (- 0.036 logMAR, + 1.8 letters). Pre-planned subgroup analyses showed that 100% contrast VA improved by a mean of + 2.8 letters (- 0.058 logMAR) with MD1003 and worsened by - 1.5 letters (+ 0.029 logMAR) with placebo (p = 0.45) in the subgroup of patients with PON. MD1003-treated patients also had nonsignificant improvement in logMAR at 5% contrast and in RNFL thickness and health outcome scores when compared with placebo-treated patients. There was no superiority of MD1003 vs placebo in patients with AON. The safety profile of MD1003 was similar to that of placebo. CONCLUSIONS: MD1003 did not significantly improve VA compared with placebo in patients with MS experiencing chronic visual loss. An interesting trend favoring MD1003 was observed in the subgroup of patients with PON. Treatment was overall well tolerated.
Document type :
Journal articles
Complete list of metadatas

Cited literature [35 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02157957
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Monday, June 17, 2019 - 3:51:24 PM
Last modification on : Friday, November 8, 2019 - 10:50:47 AM

File

40263_2018_Article_528.pdf
Publication funded by an institution

Identifiers

  • HAL Id : inserm-02157957, version 1

Citation

Ayman Tourbah, Olivier Gout, Alain Vighetto, Véronique Deburghgraeve, Jean Pelletier, et al.. MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study. CNS Drugs, Springer Verlag, 2018, 32 (7), pp.661-672. ⟨inserm-02157957⟩

Share

Metrics

Record views

104

Files downloads

63